Tag:
Actavis
Latest Headlines
Latest Headlines
Pharma continues parachute-building for patent cliff
Last month was a big one for pharma dealmaking, as anyone following the industry well knows. The list of deals, bids and potential deals is long--$33 billion long.
Rumors put Bayer, Onyx at the M&A altar
With the Watson Pharmaceuticals-Actavis deal wrapped up, M&A hounds need something new to sniff out. And voilá!
Watson formally unveils its $5.6B-plus deal for Actavis
Watson Pharmaceuticals has agreed to buy its Swiss-based rival Actavis. The price was about what the gossips expected: a total of $5.9 billion.
Watson set to unveil $5.9B Actavis buy, FT reports
The gossip about a Watson Pharmaceuticals-Actavis merger is about to be confirmed. Watson will pay €4.25 billion up front for the Swiss-based generics maker, Financial Times reports.
Reuters: Money lined up for Watson to buy Actavis
Reuters today cites sources saying banks are falling all over themselves to provide financing for Watson's possible acquisition of Actavis.
Reuters: Watson aims for Actavis deal this month
According to Reuters , Watson is sliding downhill toward an Actavis buyout, with an announcement possible by the end of April.
Bloomberg: Watson on verge of deal for Actavis
Watson Pharmaceuticals ( $WPI ) isn't just eyeing a deal for generics rival Actavis .
Is Watson poised to grab Actavis?
The generic world was abuzz yesterday after rumors surfaced that Watson Pharmaceuticals could buy Actavis for about $7 billion.
Serbian bribery probe highlights emerging-markets danger
A Serbian bribery probe serves up a cautionary tale for drugmakers relying on emerging markets for growth. Reuters digs into the years-long corruption investigation, relating a plot that could have...
Actavis to pay $202M in Medicaid overbilling settlements
Actavis has agreed to pay $118 million to settle claims that the U.S. government and four states overpaid for its drugs. The deal follows an $84 million settlement of similar claims filed by the
